SARS‐CoV‐2‐related and Covid‐19 vaccine‐induced thromboembolic events: A comparative review
Zeinab Mohseni Afshar, Mohammad Barary, Arefeh Babazadeh, Rezvan Hosseinzadeh, Amirmasoud Alijanpour, Seyed Rouhollah Miri, Terence T. Sio, Mark J. M. Sullman, Kristin Carson‐Chahhoud, Florian Länger, Soheil Ebrahimpour
Abstract
Since the start of the pandemic, thrombotic events have been a well-known and severe complication associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Nevertheless, the initiation of vaccination programs brought another rare yet highly fatal thrombotic event, vaccine-induced immune thrombotic thrombocytopaenia, which has caused extensive debate regarding the safety of vaccines. This review defines the thromboembolic events following infection and vaccination, identifies their risk factors, describes their pathophysiology, and discusses their management, treatment, and prevention.